More than 40 years ago in 1983, the Orphan Drug Act was passed in the US to support and incentivise the development of rare disease therapies. Despite the over 6,000 orphan drug designations (ODD) granted by the FDA since then,…
Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
Access to capital is the difference between life and death for small biotechs and life science start-ups. But in an industry with high levels of failure and decades-long development cycles,…
What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary Tissue Reforming Technology Platform (TRTP) translates developmental biology and quantitative tissue design into scaffold-free therapeutic tissue modules. He discusses the Phase II development of TRTP-101, the TRTP-201 cartilage programme, AI-enabled…
What begins as frustration with the limits of academic research has developed into a story of entrepreneurship, scientific translation and sustainable biotech growth. Dr Thomas Schirrmann, Co-Founder and CEO of…
Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into…
Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this…
Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were…
Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated…
After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the…
Boston and the Bay Area are globally renowned life science hubs, but beyond these more well-known centers of excellence lies a dense network of states and cities with enticing and…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
See our Cookie Privacy Policy Here
